Nicox (NICXF) 3-Year Book Growth Rate : -31.70% (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Nicox 3-Year Book Growth Rate?

Nicox's Book Value per Share for the quarter that ended in Jun. 2023 was $0.98.

During the past 12 months, Nicox's average Book Value per Share Growth Rate was -35.30% per year. During the past 3 years, the average Book Value per Share Growth Rate was -31.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was -24.00% per year. During the past 10 years, the average Book Value per Share Growth Rate was -11.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Nicox was 28.60% per year. The lowest was -31.70% per year. And the median was -7.80% per year.

Competitive Comparison of Nicox's 3-Year Book Growth Rate

For the Biotechnology subindustry, Nicox's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Nicox's 3-Year Book Growth Rate falls into.

Nicox 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Nicox (OTCPK:NICXF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Nicox 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Nicox's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (NICXF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ALCOX:France NXOA:Germany

Address

2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560

Website

https://www.nicox.com

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines

From GuruFocus

Bausch Health Announces VYZULTA� (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea

By PRNewswire PRNewswire • 02-09-2021